Sumatriptan Succinate And Naproxen Sodium Tablet
Product Images NDC 44183-850

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate And Naproxen Sodium (NDC 44183-850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Currax Pharmaceuticals Llc Dba Cypress, Hawthorn, Macoven, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Sumatriptan 01)

Chemical structure of sumatriptan succinate, the active ingredient in Sumatriptan Succinate and Naproxen Sodium tablets. The diagram shows the molecular arrangement with sulfonamide and indole groups, characteristic of sumatriptan succinate.*

FDA Label Image

Chemical Structure (Sumatriptan 02)

Chemical structure of naproxen sodium, showing its molecular arrangement with an aromatic ring, a methoxy group, and a sodium carboxylate group. This structure represents the active ingredient naproxen sodium in the Sumatriptan Succinate and Naproxen Sodium combination product.*

FDA Label Image

Figure 1 (Sumatriptan 03)

Line graph showing the percentage of patients with relief over two hours postdose. It compares Sumatriptan and Naproxen Sodium Tablets 85/500 mg, Sumatriptan 85 mg, Naproxen Sodium 500 mg, and Placebo. The percentage of patients with relief increases over time for all groups, with the combination tablets showing the highest relief percentage.*

FDA Label Image

Figure 2 (Sumatriptan 04)

A line chart showing the percentage of patients taking rescue medication over 24 hours postdose for four groups: Placebo, Naproxen, Sumatriptan, and Sumatriptan and Naproxen Sodium Tablets 85 mg/500 mg. The x-axis represents hours postdose from 0 to 24, and the y-axis shows the percentage of patients from 0% to 100%. The Placebo group shows the highest percentage, followed by Naproxen, then Sumatriptan, with the Sumatriptan and Naproxen Sodium Tablets 85/500 mg group showing the lowest percentage of patients needing rescue medication.*

FDA Label Image

Principal Display Panel (85 mg/500 mg Tablet Bottle Label)

Label for Sumatriptan and Naproxen Sodium Tablets, 85 mg/500 mg, oral dosage form. The label includes the active ingredient strengths, NDC 44183-850-09, and instructions to swallow tablets whole. It states the product contains 9 tablets and is distributed by Macoven. The label also highlights storage instructions and a warning not to use if the safety seal is broken or missing.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.